2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, and Martín C. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020; 21(17): 6275.
3. Klonoff DC, Aaron RE, Tian T, DuNova AY, Pandey A, Rhee C, Fleming GA, Sacks DB, Pop-Busui R, and Kerr D. Advanced Glycation End products: A Marker of Long-term Exposure to Glycemia. J Diabetes Sci Technol. 2024; 19322968241240436. doi: 10.1177/19322968241240436
4. Leow MKS. Correlation between glycated haemoglobin A1c and fasting plasma glucose level: A patient-centred approach to initiating insulin therapy. Singapore Med J. 2016; 57(2): 62
5. Kohzuma T, Tao X, and Koga, M. Glycated albumin as biomarker: Evidence and its outcomes. J Diabetes Complicat. 2021; 35(11): 108040.
6. Ferrario L, Schettini F, Avogaro A, Bellia C, Bertuzzi F, Bonetti G, Ceriello A , Ciaccio M , Romanelli MC , Dozio E , Falqui L , Girelli A , Nicolucci A , Perseghin G , Plebani M , Valentini U , Zaninotto M , Castaldi S, and Foglia E . Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. Clinicoecon Outcomes Res. 2021; 13:453-464. doi: 10.2147/CEOR.S304868.
7. Tang M, and Kalim S. In Reply to “Considerations on Potential Modifiers of Glycated Albumin Levels in Patients with CKD. Am J Kidney Dis. 2024;www.ajkd.org/article/S0272-6386 (24)00834-5/fulltext
8. Kibirige D, and Kaggwa S. Glycated Albumin, HbA1c, and Their Correlation with Glycemic Control in Patients with Type 2 Diabetes Mellitus in Uganda. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017; 10: 303-309. https://doi.org/10.2147/DMSO.S126097
9. Kiptoo P, Ouma M, and Olweny M. Glycated albumin and glycated hemoglobin as biomarkers for glycemic control in Kenyan diabetic patients. J Diabetes Res. 2019; 1-8. https://doi.org/10.1155/2019/9630564
10. Zemlin AE, Barkhuizen M, Kengne AP, Erasmus RT, and Matsha TE. Performance of glycated albumin for type 2 diabetes and prediabetes diagnosis in a South African population. Clin Chim Acta.2019; 488:122-128. doi: 10.1016/j.cca.2018.11.005
11. Kaur J, Jiang C, and Liu G. Different strategies for detection of HbA1c emphasizing on biosensors and point-of-care analyzers. Biosens Bioelectronics. 2019; 123(1):85-100
12. Rahbar S, Blumenfeld O, and Ranney H.M. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969; 36: 838–43.
13. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, and Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights. 2016; 11, BMI-S38440
14. Cavagnolli G, Pimentel AL, Freitas PAC, and Gross JL, Camargo JL. Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis. PLoS ONE 2017; 12(2): e0171315. doi:10.1371/journal. pone.0171315
15. Sharma P, Panchal A, Yadav N, and Narang J. Analytical techniques for the detection of glycated haemoglobin underlining the sensors. Int J Biol Macromol.2020; 155: 685-696.
16. Norris O, and Schermerhorn T. Relationship between HbA1c, fructosamine and clinical assessment of glycemic control in dogs. PLoS One. 2022; 17(2): e0264275.
17. Kidwai SS, Nageen A, Bashir F, and Ara J. HbA1c–A predictor of dyslipidemia in type 2 Diabetes Mellitus. Pak J Med Sci. 2020; 36(6): 1339.
18. Lau CS, and Aw TC. HbA1c in the diagnosis of diabetes mellitus: A review of its current status. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; 13: 4233-4242.
19. Rashed E, Alkout T, Eltomy S, Etekbali OR, and Alkout AM. The effects of red blood cells parameters on HbA1c and random blood sugar levels in diabetes diagnosis. Int. J. Diabetes Clin. Res. 2020; 7: 1-7.
20. Ogbera A, and Kalu O. Glycated hemoglobin and its association with clinical parameters in Nigerian adults with type 2 diabetes mellitus. J Diabetes Res. 2016; 1-8. https://doi.org/10.1155/2016/8609124
21. Akinmoladun I, and Akinmoladun F. Relationship between glycated hemoglobin levels and lipid profiles in diabetic patients. Diabetes Metab Syndr: Clin Res Rev. 2020; 14(4): 497-502. https://doi.org/10.1016/j.dsx.2020.02.011
22. Lenters-Westra E, and Slingerland RJ. Six of eight hemoglobinA1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010; 56(1): 44-52.
23. Koga M, Murai J, Saito H, Mukai M, Matsumoto S, and Kasayama S. Glycated albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects. Ann Clin Biochem. 2010; 47(1): 39-43.
24. Fisher R. American Diabetes Association Releases 2023 Standards of Care in Diabetes to Guide Prevention, Diagnosis, and Treatment for People Living with Diabetes. Diabetes Care. 2023; 46: 1715.
25. Zhou S, Dong R, Wang J, Zhang L, Yu B., Shao X., Bai P, Zhang R, Ma Y, and Yu P. Red blood cell lifespan< 74 days can clinically reduce Hb1Ac levels in type 2 diabetes. J Pers Med. 2022; 12(10): 1738.
26. Freitas PA, Ehlert LR, and Camargo JL. Glycated albumin: A potential biomarker in diabetes. Arch Endocrinol Metab. 2017; 61(3): 296-304. https://doi.org/10.1590/2359-3997000000277
27. Moman RN, Gupta N, and Varacallo M. Physiology, Albumin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024. Updated December 26, 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459198/
28. Neelofar K, and Ahmad J. Amadori albumin in diabetic nephropathy. Indian J Endocrinol Metab. 2015; 19(1): 39-46.
29. Giglio RV, Lo Sasso B, Agnello L, Bivona G, Maniscalco R, Ligi, D Mannello F, and Ciaccio M. Recent updates and advances in the use of glycated albumin for the diagnosis and monitoring of diabetes and renal, cerebro-and cardio-metabolic diseases. J Clin Med. 2020; 9(11): 3634.
30. Ueda Y, and Matsumoto H. Recent topics in chemical and clinical research on glycated albumin. JDST. 2015; 9(2): 177-182. https://doi.org/10.1177/1932296814567225
31. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R., Yong A, Striker GE and Vlassara H. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2015; 115(4): 526-532.e28. https://doi.org/10.1016/j.jada.2014.12.018
32. Fishman SL, Sonmez H, Basman C, Singh V, and Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018; 24: 1-12.
33. Rao NL, Kotian GB, Shetty JK, Shelley BP, Dmello, MK, Lobo EC Shankar SP, Almeida SD, and Shah SR. Receptor for advanced glycation end product, organ crosstalk, and pathomechanism targets for comprehensive molecular therapeutics in diabetic ischemic stroke. Biomolecules. 2022; 12(11): 1712
34. Liu T, Zhang L, Joo D, and Sun SC. NF-Κb signaling in inflammation. Signal Transduct Target Ther. 2017; 2(1): 1-9.
35. Caturano A. D’Angelo M, Mormone A, Russo V, Mollica MP, Salvatore T, Galiero R , Rinaldi L , Vetrano E , Marfella R , Monda M , Giordano A, and Sasso FC. Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. Curr Issues Mol Biol. 2023; 45: 6651–6666. https://doi.org/ 10.3390/cimb45080420
36. Raghav A, and Ahmad J. Glycated serum albumin: a potential disease marker and an intermediate index of diabetes control. Diabetes Metab Syndr: Clin Res Rev. 2014; 8(4): 245-251.
37. Rescalli A, Varoni EM, Cellesi F, and Cerveri P. Analytical challenges in diabetes management: towards glycated albumin point-of-care detection. Biosensors. 2022; 12(9): 687.
38. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, and Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. JDST. 2011; 5(6): 1455-1462.
39. Chume FC, Schiavenin LG, Freitas PAC, Pimentel AL, and Camargo JL. The usefulness of glycated albumin in patients with diabetes and renal disease: a scoping review. J Lab Precis Med. 2022; 7.
40. Sato T, Iwakura K, and Nishida T. The Lucica GA-L® enzymatic assay: Advancements in glycated albumin measurement. J Clin Biochem. 2015; 48(5): 388-392. https://doi.org/10.1016/j.jcfm.2015.02.004
41. Tsai SH, Hsu CC, and Lin CY. Advances in Methods for Measuring Glycated Albumin. J Clin Lab Anal. 2017; 31(3): e22041. https://doi.org/10.1002/jcla.22041.
42. Kohzuma K, Hoshino T, and Yamashita H. Stability of Glycated Albumin in Frozen Serum Samples. Clin Chem. 2007; 53(5): 861-867. https://doi.org/10.1373/clinchem.2006.085796.
43. Watano T, Sasaki K, Omoto K, and Kawano M. Stability of stored samples for assays of glycated albumin. Diabetes Res Clin Pr. 2013; 101(1): e1-e2.
44. Kohzuma T, Tao X, and Koga M. Glycated albumin as biomarker: Evidence and its outcomes. J Diabetes Complications. 2021; 35(11): 108040.
45. Silva JF, Pimentel AL, and Camargo JL. Effect of iron deficiency anaemia on HbA1c levels is dependent on the degree of anaemia. Clin Biochem. 2016; 49(1-2): 117-120.
46. Suzuki S, and Koga M. Glycemic control indicators in patients with neonatal diabetes mellitus. World J Diabetes. 2014; 5(2):198-208. doi: 10.4239/wjd.v5.i2.198.
47. Chen Z, Shao L, Jiang M, Ba X, Ma B, and Zhou T. Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review) Corrigendum in/10.3892/etm. 2023.11885. Exp Ther Med. 2022; 24(6): 1-11.
48. Fang M. Trends in diabetes management among US adults: 1999–2016. J Gen Intern Med. 2020; 35: 1427-1434.
49. Hashimoto H, Murakami H, and Sato Y. Stability of Glycated Albumin in Pregnant Women with Diabetes: A Prospective Study. Diabetes Res Clin Pr. 2020; 163: 108130. https://doi.org/10.1016/j.diabres.2020.108130.
50. Cavagnolli G, Pimentel AL, Freitas PAC, Gross JL, and Camargo JL. Factors affecting A1C in non-diabetic individuals: Review and meta-analysis. Clinica Chimica Acta. 2015; 445: 107-114.
51. Chachou A, Randoux C, Millart H, Chanard J, and Gillery P. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med. 2000; 38(4):321-6. doi: 10.1515/CCLM.2000.046.
52. Carson AP, Reynolds K, Fonseca VA, and Muntner, P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among US adults. Diabetes Care. 2010; 33(1): 95-97.
53. Danese E, Montagnana M, Nouvenne A, and Lippi G. Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. JDST. 2015; 9(2): 169-176.
54. Wang BR, Yao JT, Zheng H, and Li QM. Association of Glycated Albumin/Glycosylated Hemoglobin Ratio with Blood Glucose Fluctuation and Long-Term Blood Glucose Control in Patients with Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes. 2021;14:1809-1815. doi: 10.2147/DMSO.S297730
55. Nathan DM, Lachin JM, and Cleary PA. The effect of intensive treatment of diabetes on the development and progression of long-term complications in type 1 diabetes: The DCCT/EDIC study. Diabetes. 2014; 63(12): 487-494. https://doi.org/10.2337/db13-1801
56. Selvin E, Steffes M, and Zhu H. Glycated albumin and glycated hemoglobin in predicting diabetes complications: Evidence from the Atherosclerosis Risk in Communities study. Diabetes Care. 2016; 39(6): 809-816. https://doi.org/10.2337/dc15-2431
57. Selvin E, Steffes MW, Ballantyne CM, Hoogeveen RC, Coresh J, and Brancati FL. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med. 2011; 154(5): 303-309.
58. Nathan DM, McGee P, Steffes MW, Lachin JM, and DCCT/EDIC research group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014; 63(1): 282-290.
59. Gan T, Liu X, and Xu G. Glycated Albumin versus HbA1c in the Evaluation of Glycemic Control in Patients With Diabetes and CKD. Kidney Int Rep. 2018; 3(3): 542–554. doi: 10.1016/j.ekir.2017.11.009
60. Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, and Ono J. Report of the committee on standardization of laboratory testing related to diabetes mellitus of the Japan diabetes society: Determination of reference intervals of hemoglobin A1C (IFCC) and glycoalbumin in the Japanese population. J Japan Diabetes Soc. 2005; 49(10):825-833
61. Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, and Hayashi J. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia. 2011; 54:3028–3036 DOI 10.1007/s00125-011-2310-6
62. Ikezaki H, Furusyo N, Ihara T, Hayashi T, Ura K, Hiramine S, Mitsumoto F , Takayama K , Murata M , Kohzuma T , Ai M , Schaefer EJ, and Hayashi J. Glycated albumin as a diagnostic tool for diabetes in a general Japanese population. Metabolism. 2015; 64(6):698-705. doi: 10.1016/j.metabol.2015.03.003
63. Hwang YC, Jung CH, Ahn HY, Jeon WS, Jin SM, Woo JT, Cha BS , Kim JH , Park C-Y, and Lee B-W. Optimal glycated albumin cutoff value to diagnose diabetes in Korean adults: a retrospective study based on the oral glucose tolerance test. Clinica Chimica Acta, 2014; 437: 1-5.
64. Hsu T, Yang S, and Chang H. Glycated albumin as a diagnostic marker for diabetes mellitus: A study in Taiwan. J Diabetes Res. 2019: 1-8. https://doi.org/10.1155/2019/3176048
65. Testa R, Ceriotti F, Guerra E, Bonfigli AR, Boemi M, Cucchi M, Gaetano ND, Santini G, Genovese S, and Ceriello A. Glycated albumin: correlation to HbA1c and preliminary reference interval evaluation. Clin Chem Lab Med (CCLM). 2017; 55(2): e31-e33.
66. Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, and Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia–1, 5‐anhydroglucitol, fructosamine, and glycated albumin. Pediatr Diabetes. 2016; 17(3): 206-211.
67. Xiong JY, Wang JM, Zhao XL, Yang C, Jiang XS, Chen, and YM. Glycated albumin as a biomarker for diagnosis of diabetes mellitus: A systematic review and meta-analysis. World J Clin Cases. 2021; 9(31): 9520
68. Akinmoladun I, and Akinmoladun F. Assessment of glycated albumin as a short-term glycemic marker in type 2 diabetes mellitus patients. J Diabetes Res. 2019; 1-7. https://doi.org/10.1155/2019/9827170
69. Eyth E, and Naik R. Hemoglobin A1C. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549816/
70. Parrinello CM, and Selvin E. Beyond HbA1c and glucose: the role of nontraditionalglycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep. 2014; 14: 1-10.
71. Furusyo N, and Hayashi J. Glycated albumin and diabetes mellitus. Biochimica et Biophysica Acta (BBA)-General Subjects. 2013; 1830(12): 5509-5514
72. Kengne AP, Matsha TE, Sacks DB, Zemlin AE, Erasmus RT, and Sumner AE. Combining HbA1c and glycated albumin improves detection of dysglycaemia in mixed-ancestry South Africans. E Clinical Medicine. 2022; 48.
73. Sumner AE, Duong MT, Aldana PC, Ricks M, Tulloch-Reid MK, Lozier JN, Chung ST, and Sacks DB. A1C Combined With Glycated Albumin Improves Detection of Prediabetes in Africans: The Africans in America Study. Diabetes Care. 2016; 39(2):271-7. doi: 10.2337/dc15-1699
74. Ajayi IO, Kengne AP, Sumner AE, and Zemlin AE. A1C combined with glycated albumin improves detection of dysglycaemia in Africans: The Africans in America study. Front Endocrinol. 2023. https://www.frontiersin.org/articles/10.3389/fendo.2023.1192491/full
75. Khosla L, Bhat S, Fullington LA, and Horlyck-Romanovsky MF. Peer Reviewed: HbA1c Performance in African Descent Populations in the United States with Normal Glucose Tolerance, Prediabetes, or Diabetes: A Scoping Review. Prev Chronic Dis. 2021; 18.
76. Woruka AP, and John CO. The Use of Glycated Albumin in the Diagnosis of Gestational Diabetes Mellitus. J Biosci Med. 2024; 12(01): 19-28
77. John CO, and Woruka AP. A Cross-Sectional Study on the Accuracy of Glycated Albumin in Diagnosing Pregnancies Complicated with Gestational Diabetes Mellitus. Asian Research Journal of Gynaecology and Obstetrics. 2024; 7(1): 18-26.
78. Ibrahim KG, and Abubakar MB. Association of Micro-albuminuria with Retinopathy and Glycated Haemoglobin among Type II Diabetes Patients Attending a Hospital in Bauchi. Jewel Journal of Medical Sciences (JJMesSci). 2021; 1(2):144-152
79. Seniya KM, Baiju KV, and Ambil R. Evaluation of salivary glycated albumin in periodontitis patients with and without type 2 diabetes mellitus and its changes with non-surgical periodontal therapy. Niger J Clin Pract. 2023; 26(9): 1257-1263
80. Itam AH, Ogarekpe YM, Edem B, Agboola AR, Okpara HC, and Okokon EO. Association between Serum Calcium Concentration and Glycated Haemoglobin in Type II Diabetic Nigerian Patients. BIOMED Natural and Applied Science. 2022; 2(03): 25-32.
81. Oladayo MI, Tanko V, and Yusuf R. Glycated Haemoglobin (HbA1c) and the Assessment of Risk of Nephropathy in Diabetic Patients in Ahmadu Bello University Teaching Hospital Zaria, Nigeria. J Biomed Sci, 2022; 11(9): 78.
- Abstract viewed - 135 times
- PDF downloaded - 50 times
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright
© OO Ajayi, M Timothy, 2024
Affiliations
OO Ajayi
Department of Biochemistry, Edo State University Uzairue, Edo State
M Timothy
Department of Policy, Planning, Research and Statistics, Edo State Ministry of Health, Edo State
How to Cite
COMPARATIVE ROLE OF GLYCATED HAEMOGLOBIN AND GLYCATED ALBUMIN IN THE MANAGEMENT OF DIABETES MELLITUS
Vol 10 No 2 (2024): Volume 10 Number 2
Submitted: Oct 29, 2024
Published: Oct 29, 2024
Abstract
Glycated haemoglobin (HbA1c) and glycated albumin (GA) are key biomarkers in the management of diabetes mellitus, each providing unique insights into glycaemic control. HbA1c, the traditional marker, reflects average blood glucose levels over approximately 120 days, making it essential for long-term monitoring. However, its reliability can be compromised by conditions such as anaemia, pregnancy, and chronic kidney disease. Glycated albumin, a newer marker, offers a snapshot of glycaemic fluctuations over a shorter period of 2 to 4 weeks, thus addressing some limitations of HbA1c. Recent advancements in GA measurement methodologies, particularly the Lucica GA-L® assay, have improved its precision and stability. Studies demonstrate GA's usefulness in scenarios where HbA1c may be less reliable, such as in patients with altered red blood cell life spans, during pregnancy, or in chronic kidney disease. GA
also shows promise in monitoring short-term glycaemic changes and treatment responses, offering an advantage in assessing rapid fluctuations in glucose levels. Despite its advantages, GA is not a replacement for HbA1c but rather a complementary tool that can enhance diabetes management. The choice between HbA1c and GA should be guided by individual patient conditions and clinical contexts. Future research is needed to refine GA’s diagnostic criteria, explore its effectiveness in diverse populations, and understand its role in predicting long-term diabetes complications. By integrating both markers into clinical practice, healthcare providers can improve the accuracy of glycaemic monitoring and optimize patient care.
Keywords: Diabetes mellitus, glycated haemoglobin, glycated albumin, sub-Saharan Africa